Orthopedic Biomaterials Market Report Suite - Japan - 2020 - 2026 - MedSuite
Throughout this medical market research, iData Research analyzed 16 orthobiologics companies in Japan and utilized their comprehensive methodology to understand the Market Sizes, Unit Sales, ASPs, Company Market Shares, and to create accurate forecasts.
While this MedSuitereport contains all of the Japanese Orthopedic Biomaterials market analysis, each of the market segments is also available as stand-alone MedCorereports. Additionally, this research includes an orthobiologics procedure volume analysis which can also be purchased as a separate report, MedPro.
Markets Covered
- Procedure Volumes for the Japanese Orthopedic Biomaterials Devices – MedPro
- Orthopedic Bone Graft Substitute Market - MedCore
- Hyaluronic Acid Viscosupplementation Market - MedCore
Japanese Orthopedic Biomaterials Market InsightsA lack of product differentiation across similar injection cycle products has led to commoditization, which has stifled innovation and the further development of new products. The prices of HA viscosupplementation products in Japan have drastically decreased since their introduction and are among the lowest in the world.
In August 2018, Medtronic received PMDA approval for its Grafton® DBM allograft product, which is the first DBM allograft to be approved in Japan. Grafton® was commercially launched in February 2019. Growth of this product will be primarily driven by spine procedures and other orthopedic procedures that it is indicated for.
Overall, the Japanese orthopedic biomaterials market was valued at $426.9 million in 2019. This is expected to fluctuate over the forecast period with a -0.4% CAGR.
The full report suite on the Japan market for orthopedic biomaterials includes bone graft substitutes, which are represented by synthetics and DBM allografts. DBM allografts are discussed qualitatively. This report also includes hyaluronic acid (HA) viscosupplementation.
- EXECUTIVE SUMMARY
- JAPANESE ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW
- COMPETITIVE ANALYSIS
- MARKET TRENDS
- MARKET DEVELOPMENTS
- PROCEDURE NUMBERS
- MARKETS INCLUDED
- VERSION HISTORY
- RESEARCH METHODOLOGY
- Step 1: Project Initiation & Team Selection
- Step 2: Prepare Data Systems and Perform Secondary Research
- Step 3: Preparation for Interviews & Questionnaire Design
- Step 4: Performing Primary Research
- Step 5: Research Analysis: Establishing Baseline Estimates
- Step 6: Market Forecast and Analysis
- Step 7: Identify Strategic Opportunities
- Step 8: Final Review and Market Release
- Step 9: Customer Feedback and Market Monitoring
- PRODUCT ASSESSMENT
- 2.1 INTRODUCTION
- 2.2 PRODUCT PORTFOLIOS
- 2.2.1 Bone Graft Substitutes
- 2.2.2 Growth Factors
- 2.2.2.1 Other Products
- 2.2.3 Hyaluronic Acid Viscosupplementation (HAV)
- 2.3 REGULATORY ISSUES AND RECALLS
- 2.3.1 Bone Graft Substitutes
- 2.3.1.1 Allografts
- 2.3.1.1.1 MTF
- 2.3.1.2 DBM
- 2.3.1.2.1 AlloSource
- 2.3.1.2.2 SeaSpine
- 2.3.1.2.3 RTI Surgical
- 2.3.1.3 Synthetics
- 2.3.1.3.1 Abyrx
- 2.3.1.3.2 Zimmer Biomet
- 2.3.2 Growth Factors
- 2.3.2.1.1 Medtronic
- 2.3.3 Hyaluronic Acid Viscosupplementation
- 2.3.3.1 Three-injection
- 2.3.3.1.1 Ferring Pharmaceuticals
- 2.4 CLINICAL TRIALS
- 2.4.1 Bone Graft Substitutes
- 2.4.1.1 Allografts
- 2.4.1.1.1 Providence Medical Technology
- 2.4.1.1.2 The University of Texas Health Science
- 2.4.1.1.3 University of Winchester
- 2.4.1.2 BDM
- 2.4.1.2.1 K2M
- 2.4.1.2.2 Zimmer Biomet
- 2.4.1.3 Synthetics
- 2.4.1.3.1 Baxter
- 2.4.1.3.2 Bonesupport
- 2.4.1.3.3 DePuy Synthes
- 2.4.1.3.4 NuVasive
- 2.4.1.3.5 RTI surgical
- 2.4.1.3.6 Sunstar GUIDOR
- 2.4.1.4 Other materials and comparison
- 2.4.1.4.1 Seoul National University Hospital.
- 2.4.1.4.2 Sewon Cellontech
- 2.4.1.4.3 SurgaColl Technologies Limited
- 2.4.1.4.4 University of Colorado
- 2.4.1.4.5 University of Padova
- 2.4.2 Growth Factors
- 2.4.2.1.1 Bioventus
- 2.4.2.1.2 Cerapedics
- 2.4.2.1.3 CGBio
- 2.4.2.1.4 Isto
- 2.4.2.1.5 Medtronic
- 2.4.2.1.6 NuVasive
- 2.4.2.1.7 Wright
- 2.4.2.1.8 Others
- 2.4.3 Hyaluronic Acid Viscosupplementation
- 2.4.3.1.1 Anika Therapeutics
- 2.4.3.1.2 Bioventus
- 2.4.3.1.3 Cairo University
- 2.4.3.1.4 Ferring Pharmaceuticals
- 2.4.3.1.5 Federal University of Minas Gerais
- 2.4.3.1.6 Fidia Pharma USA Inc.
- 2.4.3.1.7 Istituto Ortopedico Rizzoli
- 2.4.3.1.8 University Hospital
- 2.4.3.1.9 Universidade Nova de Lisboa
- JAPAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW
- 3.1 INTRODUCTION
- 3.1.1 Bone Graft Substitutes
- 3.1.2 Growth Factors
- 3.1.3 Hyaluronic Acid (HA) Viscosupplementation
- 3.2 CURRENCY EXCHANGE RATE
- 3.3 MARKET OVERVIEW AND TREND ANALYSIS
- 3.4 DRIVERS AND LIMITERS
- 3.4.1 Market Drivers
- 3.4.2 Market Limiters
- 3.5 COMPETITIVE MARKET SHARE ANALYSIS
- 3.6 MERGERS AND ACQUISITIONS
- 3.7 COMPANY PROFILES
- 3.7.1 Anika Therapeutics
- 3.7.2 Bioventus
- 3.7.3 DePuy Synthes
- 3.7.4 Ferring Pharmaceuticals
- 3.7.5 Fidia Pharmaceuticals
- 3.7.6 Genzyme (Sanofi Group)
- 3.7.7 Harvest Technologies (Terumo BCT)
- 3.7.8 Integra LifeSciences
- 3.7.9 Medtronic
- 3.7.10 Musculoskeletal Transplant Foundation (MTF)
- 3.7.11 NuVasive
- 3.7.12 Orthofix
- 3.7.13 RTI Surgical
- 3.7.14 Stryker
- 3.7.15 Vericel Corporation (formerly Aastrom Bioscience)
- 3.7.16 Zimmer Biomet
- 3.8 SWOT ANALYSIS
- 3.8.1 Anika Therapeutics
- 3.8.2 Bioventus
- 3.8.3 DePuy Synthes
- 3.8.4 Ferring Pharmaceuticals
- 3.8.5 Fidia Pharmaceuticals
- 3.8.7 Harvest Technologies (Terumo BCT)
- 3.8.8 Integra LifeSciences
- 3.8.9 Medtronic
- 3.8.10 Musculoskeletal Transplant Foundation (MTF)
- 3.8.11 NuVasive
- 3.8.12 Orthofix
- 3.8.14 Stryker
- 3.8.15 Vericel Corporation (formerly Aastrom Bioscience)
- 3.8.16 Zimmer Biomet
- PROCEDURE NUMBERS
- 4.1 INTRODUCTION
- 4.2 PROCEDURES
- 4.2.1 Orthopedic Biomaterial Procedures by Segment
- 4.2.2 Orthopedic Bone Grafting Procedures
- 4.2.2.1 Units per Procedure by Indication
- 4.2.2.2 Autograft Orthopedic Bone Grafting Procedures by Indication
- 4.2.2.3 Synthetic Orthopedic Bone Grafting Procedures by Indication
- 4.2.3 Hyaluronic Acid Supplementation Procedures
- 4.2.3.1 Hyaluronic Acid Supplementation Procedures by Injection Cycle
- ORTHOPEDIC BONE GRAFT SUBSTITUTE MARKET
- 5.1 INTRODUCTION
- 5.2 MARKET ANALYSIS AND FORECAST
- 5.2.1.1 Synthetic Bone Graft Substitute Market
- 5.2.1.1.1 Synthetic Bone Graft Substitute Market by Indication
- 5.2.1.2 Demineralized Bone Matrix Allograft Bone Graft Substitute Market
- 5.3 DRIVERS AND LIMITERS
- 5.3.1 Market Drivers
- 5.3.2 Market Limiters
- 5.4 COMPETITIVE MARKET SHARE ANALYSIS
- HYALURONIC ACID VISCOSUPPLEMENTATION MARKET
- 6.1 INTRODUCTION
- 6.1.1 Benefits of Viscosupplementation
- 6.1.2 Synovial Fluid
- 6.2 MARKET OVERVIEW
- 6.3 MARKET ANALYSIS AND FORECAST
- 6.3.1 Total Hyaluronic Acid Viscosupplementation Market
- 6.3.2 Three-Injection Hyaluronic Acid Viscosupplementation Market
- 6.3.3 Five-Injection Hyaluronic Acid Viscosupplementation Market
- 6.4 DRIVERS AND LIMITERS
- 6.4.1 Market Drivers
- 6.4.2 Market Limiters
- 6.5 COMPETITIVE MARKET SHARE ANALYSIS
- ABBREVIATIONS
- List of Charts
- Chart 1 1: Orthopedic Biomaterials Market by Segment, Japan, 2016 – 2026
- Chart 1 2: Orthopedic Biomaterials Market Overview, Japan, 2019 & 2026
- Chart 3 1: Orthopedic Biomaterials Market by Segment, Japan, 2016 – 2026
- Chart 3 2: Orthopedic Biomaterials Market Breakdown, Japan, 2019
- Chart 3 3: Orthopedic Biomaterials Market Breakdown, Japan, 2026
- Chart 3 4: Growth Rates by Segment, Orthopedic Biomaterials Market, Japan, 2017 – 2026
- Chart 3 5: Leading Competitors, Orthopedic Biomaterials Market, Japan, 2019
- Chart 4 1: Orthopedic Biomaterials Procedures by Segment, Japan, 2016 – 2026
- Chart 4 2: Orthopedic Bone Grafting Procedures by Material, Japan, 2016 – 2026
- Chart 4 3: Autograft Orthopedic Procedures by Indication, Japan, 2016 – 2026
- Chart 4 4: Synthetic Orthopedic Bone Grafting Procedures by Indication, Japan, 2016 – 2026
- Chart 4 5: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Japan, 2016 – 2026
- Chart 5 1: Synthetic Bone Graft Substitute Market, Japan, 2016 – 2026
- Chart 5 2: Synthetic Bone Graft Substitute Market by Indication, Japan, 2016 – 2026
- Chart 5 3: Spine Synthetic Market, Japan, 2016 – 2026
- Chart 5 4: Cervical Spine Synthetic Market, Japan, 2016 – 2026
- Chart 5 5: Thoracolumbar Spine Synthetic Market, Japan, 2016 – 2026
- Chart 5 6: Trauma Synthetic Market, Japan, 2016 – 2026
- Chart 5 7: Non-Union Trauma Synthetic Market, Japan, 2016 – 2026
- Chart 5 8: Fresh Fracture Trauma Synthetic Market, Japan, 2016 – 2026
- Chart 5 9: Large Joint Reconstruction Synthetic Market, Japan, 2016 – 2026
- Chart 5 10: Hip Reconstruction Synthetic Market, Japan, 2016 – 2026
- Chart 5 11: Knee Reconstruction Synthetic Market, Japan, 2016 – 2026
- Chart 5 12: Foot Reconstruction Synthetic Market, Japan, 2016 – 2026
- Chart 5 13: Craniomaxillofacial Synthetic Market, Japan, 2016 – 2026
- Chart 5 14: Oncology Synthetic Market, Japan, 2016 – 2026
- Chart 5 15: Leading Competitors, Orthopedic Bone Graft Substitute Market, Japan, 2019
- Chart 6 1: Hyaluronic Acid Viscosupplementation Market by Segment, Japan, 2016 – 2026
- Chart 6 2: Hyaluronic Acid Viscosupplementation Market Breakdown, Japan, 2019
- Chart 6 3: Hyaluronic Acid Viscosupplementation Market Breakdown, Japan, 2026
- Chart 6 4: Total Hyaluronic Acid Viscosupplementation Market, Japan, 2016 – 2026
- Chart 6 5: Three-Injection Hyaluronic Acid Viscosupplementation Market, Japan, 2016 – 2026
- Chart 6 6: Five-Injection Hyaluronic Acid Viscosupplementation Market, Japan, 2016 – 2026
- Chart 6 7: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, Japan,
- LiST OF Figures
- Figure 1 1: Orthopedic Biomaterials Market Share Ranking by Segment, Japan, 2019
- Figure 1 2: Companies Researched in this Report
- Figure 1 3: Factors Impacting the Orthopedic Biomaterials Market by Segment, Japan
- Figure 1 4: Recent Events in the Orthopedic Biomaterials Market, Japan, 2017 – 2019
- Figure 1 5: Orthopedic Biomaterials Procedures Covered, Japan
- Figure 1 6: Orthopedic Biomaterials Markets Covered, Japan
- Figure 1 7: Version History
- Figure 2 1: Bone Graft Substitutes Products by Company (1 of 4)
- Figure 2 2: Bone Graft Substitutes Products by Company (2 of 4)
- Figure 2 3: Bone Graft Substitutes Products by Company (3 of 4)
- Figure 2 4: Bone Graft Substitutes Products by Company (4 of 4)
- Figure 2 5: Growth Factor Products by Company
- Figure 2 6: Hyaluronic Acid Viscosupplementation by Products by Company
- Figure 2 7: Class 2 Device Recall Musculoskeletal Transplant Foundation Allofix Insertion Kit
- Figure 2 8: Class 2 Device Recall AlloFuse DBM Putty 5cc
- Figure 2 9: Class 2 Device Recall Accell Evo3c Demineralized Bone Matrix Putty
- Figure 2 10: Class 2 Device Recall RTI Biologics BioSet IC RT Paste 2 cc
- Figure 2 11: Class 2 Device Recall Hemostatic Bone Putty
- Figure 2 12: Class 2 Device Recall Endobon Xenograft Granules
- Figure 2 13: Class 2 Device Recall Endobon Xenograft Granules
- Figure 2 14: Class 2 Device Recall INFUSE Bone Graft X SMALL KIT
- Figure 2 15: Class 3 Device Recall Euflexxa (1 sodium hyaluronate)
- Figure 2 16: Evaluation of DTRAX Graft in Patients with Cervical Degenerative Disc Disease
- Figure 2 17: Ridge Preservation Using FDBA and a Collagen Wound Dressing in Molar Sites.
- Figure 2 18: Assessing Physical Activity Levels of Patients Following HTO.
- Figure 2 19: Evaluation of Fusion Rate Using K2M VESUVIUS® Demineralized Fibers with K2M EVEREST® Spinal System
- Figure 2 20: Evaluation of Zimmer Puros® Allograft vs. Creos™ Allograft for Alveolar Ridge Preservation
- Figure 2 21: Synthetic Bone Graft Substitute vs. Autologous Spongiosa in Revision Anterior Cruciate Ligament Reconstruction
- Figure 2 22: Cerament Treatment of Fracture Defects (CERTiFy)
- Figure 2 23: Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute (BAGvsTCP)
- Figure 2 24: Evaluation of Fusion Rate of Anterior Cervical Discectomy and Fusion (ACDF) Using Cervios ChronOs™ and Bonion™
- Figure 2 25: AttraX® Putty vs. Autograft in XLIF®
- Figure 2 26: Comparison of nanOss Bioactive with Autograft and Bone Marrow Aspirate to Autograft in the Posterolateral Spine
- Figure 2 27: Assessment of nanOss Bioactive 3D in the Posterolateral Spine
- Figure 2 28: Assessment of Ridge Preservation Using Moldable Beta-tricalcium Phosphate Bone Grafting System
- Figure 2 29: Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy
- Figure 2 30: Efficacy and Safety of SurgiFill™ on Spinal Fusion
- Figure 2 31: Assessment of HydroxyColl Bone Graft Substitute in High Tibial Osteotomy Wedge Grafting. (HColl_HTO)
- Figure 2 32: Outcomes of the Evans Calcaneal Lengthening Based on Bone Grafting Material
- Figure 2 33: Deproteinized Bovine Bone in Alveolar Bone Critical Size Defect (>2cm) Secondary to Cyst Removal
- Figure 2 34: A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP®
- Figure 2 35: The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumented Posterolateral Spondylodesis Operation
- Figure 2 36: Clinical Study of Injectable Ceramics Bone Graft Substitute Containing rhBMP-2
- Figure 2 37: Prospective Study of Safety and Efficacy of InQu® Bone Graft Extender in Lumbar Interbody Fusion Surgery (Intebody)
- Figure 2 38: A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1
- Figure 2 39: Clinical Study of INFUSE® Bone Graft Compared to Autogenous Bone Graft for Vertical Ridge Augmentation
- Figure 2 40: Parallel Study Between BMP-2 and Autologous Bone Graft After Ilizarow Treatment
- Figure 2 41: RCT of AttraX® Putty vs. Autograft in Instrumented Posterolateral Spinal Fusion (AxA)
- Figure 2 42: Long-term Safety and Effectiveness of AUGMENT® Bone Graft Compared to Autologous Bone Graft
- Figure 2 43: rhBMP-2 vs Autologous Bone Grafting for the Treatment of Non-union of the Docking Site in Tibial Bone Transport
- Figure 2 44: Evaluation of Radiculitis Following Use of Bone Morphogenetic Protein-2 for Interbody Arthrodesis in Spinal Surgery
- Figure 2 45: Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow-Up (Cingal17-02)
- Figure 2 46: HyaloFAST Trial for Repair of Articular Cartilage in the Knee (FastTRACK)
- Figure 2 47: Effectiveness of Two Hyaluronic Acids in Osteoarthritis of the Knee
- Figure 2 48: The Effect of Topical Application of Hyaluronic Acid on Immediate Dental Implant
- Figure 2 49: To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knees After Hyaluronic Acid Injection
- Figure 2 50: Use of Hyaluronic Acid as a Therapeutic Strategy for Bone Repair in Humans
- Figure 2 51: Two Weekly Intra-articular Hyaluronan Knee Injections, Given One Week Apart, of HYMOVIS Combined With a Physical Exercise Program (PEP) Compared to PEP Alone, in a Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA)
- Figure 2 52: Comparative Assessment of Viscosupplementation With Polynucleotides and Hyaluronic Acid (PNHA1401)
- Figure 2 53: Trial Comparing Botulin Toxin Versus Hyaluronic Acid by Intra-articular Injection (GOTOX)
- Figure 2 54: Trial to Assess the Structural Effect and Long-term Symptomatic Relief of Intra-articular Injections of HA (ViscOA)
- Figure 3 1: Currency Exchange Rate, 2019
- Figure 3 2: Orthopedic Biomaterials Market by Segment, Japan, 2016 – 2026 (US$M)
- Figure 3 3: Orthopedic Biomaterials Market by Segment, Japan, 2016 – 2026 (JP¥M)
- Figure 3 4: Orthopedic Biomaterials Market Growth by Segment, Japan, 2016 – 2026
- Figure 3 5: Drivers and Limiters, Orthopedic Biomaterials Market, Japan, 2019
- Figure 3 6: Leading Competitors, Orthopedic Biomaterials Market, Japan, 2019
- Figure 3 7: SWOT Analysis, Anika Therapeutics (1 of 2)
- Figure 3 8: SWOT Analysis, Anika Therapeutics (2 of 2)
- Figure 3 9: SWOT Analysis, Bioventus (1 of 2)
- Figure 3 10: SWOT Analysis, Bioventus (2 of 2)
- Figure 3 11: SWOT Analysis, DePuy Synthes
- Figure 3 12: SWOT Analysis, Ferring Pharmaceuticals
- Figure 3 13: SWOT Analysis, Fidia Pharmaceuticals
- Figure 3 14: SWOT Analysis, Genzyme (Sanofi)
- Figure 3 15: SWOT Analysis, Harvest Technologies
- Figure 3 16: SWOT Analysis, Integra LifeSciences
- Figure 3 17: SWOT Analysis, Medtronic
- Figure 3 18: SWOT Analysis, MTF
- Figure 3 19: SWOT Analysis, NuVasive
- Figure 3 20: SWOT Analysis, Orthofix
- Figure 3 21: SWOT Analysis, RTI Surgical
- Figure 3 22: SWOT Analysis, Stryker
- Figure 3 23: SWOT Analysis, Vericel Corporation
- Figure 3 24: SWOT Analysis, Zimmer Biomet (1 of 2)
- Figure 3 25: SWOT Analysis, Zimmer Biomet (2 of 2)
- Figure 4 1: Orthopedic Biomaterials Procedures by Segment, Japan, 2016 – 2026
- Figure 4 2: Orthopedic Bone Grafting Procedures by Material, Japan, 2016 – 2026
- Figure 4 3: Units per Procedure by Indication, Bone Graft Substitute Market, Japan, 2016– 2026
- Figure 4 4: Autograft Orthopedic Procedures by Indication, Japan, 2016 – 2026 (1 of 2)
- Figure 4 5: Autograft Orthopedic Procedures by Indication, Japan, 2016 – 2026 (2 of 2)
- Figure 4 6: Synthetic Orthopedic Bone Grafting Procedures by Indication, Japan, 2016 – 2026 (1 of 2)
- Figure 4 7: Synthetic Orthopedic Bone Grafting Procedures, Japan, 2016 – 2026 (2 of 2)
- Figure 4 8: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, Japan, 2016 – 2026
- Figure 5 1: Synthetic Bone Graft Substitute Market, Japan, 2016 – 2026
- Figure 5 2: Synthetic Bone Graft Substitute Market by Indication, Japan, 2016 – 2026 (US$M)
- Figure 5 3: Spine Synthetic Market, Japan, 2016 – 2026
- Figure 5 4: Cervical Spine Synthetic Market, Japan, 2016 – 2026
- Figure 5 5: Thoracolumbar Spine Synthetic Market, Japan, 2016 – 2026
- Figure 5 6: Trauma Synthetic Market, Japan, 2016 – 2026
- Figure 5 7: Non-Union Trauma Synthetic Market, Japan, 2016 – 2026
- Figure 5 8: Fresh Fracture Trauma Synthetic Market, Japan, 2016 – 2026
- Figure 5 9: Large Joint Reconstruction Synthetic Market, Japan, 2016 – 2026
- Figure 5 10: Hip Reconstruction Synthetic Market, Japan, 2016 – 2026
- Figure 5 11: Knee Reconstruction Synthetic Market, Japan, 2016 – 2026
- Figure 5 12: Foot Reconstruction Synthetic Market, Japan, 2016 – 2026
- Figure 5 13: Craniomaxillofacial Synthetic Market, Japan, 2016 – 2026
- Figure 5 14: Oncology Synthetic Market, Japan, 2016 – 2026
- Figure 5 15: Drivers and Limiters, Orthopedic Bone Graft Substitute Market, Japan, 2019
- Figure 5 16: Leading Competitors, Orthopedic Bone Graft Substitute Market, Japan, 2019
- Figure 6 1: Hyaluronic Acid Viscosupplementation Market by Segment, Japan, 2016 – 2026 (US$M)
- Figure 6 2: Hyaluronic Acid Viscosupplementation Market by Segment, Japan, 2016 – 2026 (JP¥M)
- Figure 6 3: Total Hyaluronic Acid Viscosupplementation Market, Japan, 2016 – 2026
- Figure 6 4: Three-Injection Hyaluronic Acid Viscosupplementation Market, Japan, 2016 – 2026
- Figure 6 5: Five-Injection Hyaluronic Acid Viscosupplementation Market, Japan, 2016 – 2026
- Figure 6 6: Drivers and Limiters, Hyaluronic Acid Viscosupplementation Market, Japan, 2019
- Figure 6 7: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, Japan, 2019